The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
Targeting Liver Fibrosis: Strategies for Development and Validation of Antifibrotic Therapies†
Open accessAbstract
We have made striking progress in our understanding of the biochemistry and cell biology that underlies liver fibrosis and cirrhosis, including the development of strategies and agents to prevent and reverse fibrosis. However, translation of this knowledge into clinical practice has been hampered by (1) the limitation of many in vitro and in vivo models to confirm mechanisms and to test antifibrotic agents, and (2) the lack of sensitive methodologies to quantify the degree of liver fibrosis and the dynamics of fibrosis progression or reversal in patients. Furthermore, whereas cirrhosis and subsequent decompensation are accepted hard clinical endpoints, fibrosis and fibrosis progression alone are merely plausible surrogates for future clinical deterioration. In this review we focus on an optimized strategy for preclinical antifibrotic drug development and highlight the current and future techniques that permit noninvasive assessment and quantification of liver fibrosis and fibrogenesis. The availability of such noninvasive methodologies will serve as the pacemaker for the clinical development and validation of potent antifibrotic agents. (Hepatology 2009.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842 · cited 2×
“They can therefore address (1) HSC activation and recruitment, (2) activation of cells upstream of HSC activation, (3) profibrogenic growth factors, cytokines and other mediators, (4) intracellular profibrogenic pathways in HSC and cells upstream of their activation, and (5) stimulation of fibrolytic processes to reve…”
BackgroundTransient elastography: a new noninvasive method for assessment of hepatic fibrosis
Sandrin, L., Fourquet, B., Hasquenoph, J.-M., Yon, S., Fournier, C., Mal, F., Christidis, C., Ziol, M., Poulet, B., Kazemi, F., et al. (2003) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2003.07.001 · Cited by 2,738
Sampling Variability of Liver Fibrosis in Chronic Hepatitis C
Bedossa, P., Dargère, D., & Paradis, V. (2003) · Hepatology · doi:10.1016/j.hep.2003.09.022 · Cited by 2,376
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection
Regev, A., Berho, M. E., Jeffers, L. J., Milikowski, C., Molina, E. G., Pyrsopoulos, N., Feng, Z.-Z., Reddy, K. R., & Schiff, E. R. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04396-4 · Cited by 2,093
Schuppan, D., & Afdhal, N. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60383-9 · Cited by 2,089
Self-citationMunger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Bravo, A. A., Sheth, S. G., & Chopra, S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102153440706 · Cited by 2,041
Cited by
Pathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
Recent Developments in Myofibroblast Biology
Hinz, B., Phan, S. H., Thannickal, V. J., Prunotto, M., Desmoulière, A., Varga, J., De Wever, O., Mareel, M., & Gabbiani, G. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.02.004 · Cited by 1,193
Hepatic fibrosis: concept to treatment
Trautwein, C., Friedman, S. L., Schuppan, D., & Pinzani, M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.039 · Cited by 677
“Numerous compounds seem to have an adequate safety profile in animal models and in phase 1 clinical studies, or alternatively the drug is an existing agent used for other clinical indications, and is re-discovered as an antifibrotic (‘‘drug repositioning’’) [26,34].”
BackgroundSelf-citationEvolving therapies for liver fibrosis
Schuppan, D., & Kim, Y. O. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66028 · Cited by 595
Self-citationEvolving challenges in hepatic fibrosis
Friedman, S. L. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.97 · Cited by 581
The good and the bad collagens of fibrosis – Their role in signaling and organ function
Karsdal, M. A., Nielsen, S. H., Leeming, D. J., Langholm, L. L., Nielsen, M. J., Manon-Jensen, T., Siebuhr, A., Gudmann, N. S., Rønnow, S., Sand, J. M., et al. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.014 · Cited by 509
Self-citationDeterminants of Fibrosis Progression and Regression in NASH
Schuppan, D., Surabattula, R., & Wang, X. Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.012 · Cited by 479
Self-citationZeisberg, M., & Kalluri, R. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00328.2012 · Cited by 462
Liver fibrosis: Direct antifibrotic agents and targeted therapies
Schuppan, D., Ashfaq-Khan, M., Yang, A. T., & Kim, Y. O. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.04.006 · Cited by 435
Self-citationClinical evidence for the regression of liver fibrosis
Ellis, E. L., & Mann, D. A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.09.024 · Cited by 411
Fuchs, B. C., Hoshida, Y., Fujii, T., Wei, L., Yamada, S., Lauwers, G. Y., McGinn, C. M., DePeralta, D. K., Chen, X., Kuroda, T., et al. (2014) · Hepatology · doi:10.1002/hep.26898 · Cited by 351
Aoyama, T., Paik, Y.-H., Watanabe, S., Laleu, B., Gaggini, F., Fioraso-Cartier, L., Molango, S., Heitz, F., Merlot, C., Szyndralewiez, C., et al. (2012) · Hepatology · doi:10.1002/hep.25938 · Cited by 336
Liedtke, C., Luedde, T., Sauerbruch, T., Scholten, D., Streetz, K., Tacke, F., Tolba, R., Trautwein, C., Trebicka, J., & Weiskirchen, R. (2013) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-6-19 · Cited by 335
Asahina, K., Zhou, B., Pu, W. T., & Tsukamoto, H. (2011) · Hepatology · doi:10.1002/hep.24119 · Cited by 308
Ikenaga, N., Peng, Z.-W., Vaid, K. A., Liu, S. B., Yoshida, S., Sverdlov, D. Y., Mikels-Vigdal, A., Smith, V., Schuppan, D., & Popov, Y. V. (2017) · Gut · doi:10.1136/gutjnl-2016-312473 · Cited by 295
Self-citationLoguercio, C., Andreone, P., Brisc, C., Brisc, M. C., Bugianesi, E., Chiaramonte, M., Cursaro, C., Danila, M., de Sio, I., Floreani, A., et al. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.02.008 · Cited by 267
Novel insights into the function and dynamics of extracellular matrix in liver fibrosis
Karsdal, M. A., Manon-Jensen, T., Genovese, F., Kristensen, J. H., Nielsen, M. J., Sand, J. M. B., Hansen, N.-U. B., Bay-Jensen, A.-C., Bager, C. L., Krag, A., et al. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00447.2014 · Cited by 263
Self-citationXiang, D.-M., Sun, W., Ning, B.-F., Zhou, T.-F., Li, X.-F., Zhong, W., Cheng, Z., Xia, M.-Y., Wang, X., Deng, X., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313392 · Cited by 229
Liu, S. B., Ikenaga, N., Peng, Z., Sverdlov, D. Y., Greenstein, A., Smith, V., Schuppan, D., & Popov, Y. (2016) · The FASEB Journal · doi:10.1096/fj.14-268425 · Cited by 224
Self-citationDrug targeting to the diseased liver
Poelstra, K., Prakash, J., & Beljaars, L. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.02.011 · Cited by 172
“However, this threat can be turned into an advantage if targeted constructs are used to image the target cell [172].”
BackgroundYoshida, S., Ikenaga, N., Liu, S. B., Peng, Z.-W., Chung, J., Sverdlov, D. Y., Miyamoto, M., Kim, Y. O., Ogawa, S., Arch, R. H., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.038 · Cited by 164
Self-citationPeng, Z., Ikenaga, N., Liu, S. B., Sverdlov, D. Y., Vaid, K. A., Dixit, R., Weinreb, P. H., Violette, S., Sheppard, D., Schuppan, D., et al. (2016) · Hepatology · doi:10.1002/hep.28274 · Cited by 118
Self-citationBeyond scoring: a modern interpretation of disease progression in chronic liver disease
Rosselli, M., MacNaughtan, J., Jalan, R., & Pinzani, M. (2013) · Gut · doi:10.1136/gutjnl-2012-302826 · Cited by 96
Mitra, A., Satelli, A., Yan, J., Xueqing, X., Gagea, M., Hunter, C. A., Mishra, L., & Li, S. (2014) · Hepatology · doi:10.1002/hep.27392 · Cited by 94
Chen, L., Li, L., Chen, J., Li, L., Zheng, Z., Ren, J., & Qiu, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.6466 · Cited by 83
Zhang, X.-W., Mi, S., Li, Z., Zhou, J.-C., Xie, J., Hua, F., Li, K., Cui, B., Lv, X.-X., Yu, J.-J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14266 · Cited by 48
Wu, P., Luo, X., Wu, H., Zhang, Q., Dai, Y., & Sun, M. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120311 · Cited by 37
Manco, R., Leclercq, I. A., & Clerbaux, L.-A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124115 · Cited by 36
Collagen-targeted molecular imaging in diffuse liver diseases
Zhou, I. Y., Tanabe, K. K., Fuchs, B. C., & Caravan, P. (2020) · Abdominal Radiology · doi:10.1007/s00261-020-02677-2 · Cited by 14
Yang, Y., Li, W., Liu, C., Liu, J., Yang, L., Yue, W., Yang, L., Xue, R., Zhang, K., Zhang, H., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166754 · Cited by 12
Metadata
- Authors
- Popov, Y., & Schuppan, D.
- Venue
- Hepatology
- Published
- 2009-10
- Volume
- 50
- Issue
- 4
- Pages
- 1294-1306
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2040059531
- Cited by
- 296
- References
- 128
- FWCI
- 12.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.